Fosun Pharma receives NMPA clearance for Yaopharma-developed Levofloxacin Injection

Bulletin Express05-21

Shanghai Fosun Pharmaceutical (Fosun Pharma) announced that subsidiary Yaopharma has obtained National Medical Products Administration (NMPA) approval for its self-developed Levofloxacin Injection (20 ml: 0.5 g, Chemical Class 3.2).

The injectable fluoroquinolone is cleared for 11 indications covering mild to severe infections, including hospital- and community-acquired pneumonia, acute bacterial sinusitis, skin and urinary tract infections, chronic bacterial prostatitis, and post-exposure inhalational anthrax.

Key registration details • Marketing authorisation holder & manufacturer: Yaopharma Co., Ltd. • Drug approval number: Guo Yao Zhun Zi H20264412

Investment and market context • Cumulative R&D spending: RMB1.94 million (unaudited) through April 2026. • 2025 domestic sales of comparable levofloxacin injections reached RMB1.06 billion, according to IQVIA CHPA.

Management notes that market launch will broaden Fosun Pharma’s anti-infective pipeline, while actual sales will depend on demand, competitive landscape and channel penetration, and therefore remain uncertain.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1132812937?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 18:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132812937","market":"hk","top_or_hot":-1,"title":"Fosun Pharma receives NMPA clearance for Yaopharma-developed Levofloxacin Injection","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Fosun Pharma) announced that subsidiary Yaopharma has obtained National Medical Products Administration (NMPA) approval for its self-developed Levofloxacin Injection (20 ml: 0.5 g, Chemical Class 3.2).</p>\n<p>The injectable fluoroquinolone is cleared for 11 indications covering mild to severe infections, including hospital- and community-acquired pneumonia, acute bacterial sinusitis, skin and urinary tract infections, chronic bacterial prostatitis, and post-exposure inhalational anthrax.</p>\n<p>Key registration details  \n• Marketing authorisation holder & manufacturer: Yaopharma Co., Ltd.  \n• Drug approval number: Guo Yao Zhun Zi H20264412</p>\n<p>Investment and market context  \n• Cumulative R&D spending: RMB1.94 million (unaudited) through April 2026.  \n• 2025 domestic sales of comparable levofloxacin injections reached RMB1.06 billion, according to IQVIA CHPA.</p>\n<p>Management notes that market launch will broaden Fosun Pharma’s anti-infective pipeline, while actual sales will depend on demand, competitive landscape and channel penetration, and therefore remain uncertain.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma receives NMPA clearance for Yaopharma-developed Levofloxacin Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma receives NMPA clearance for Yaopharma-developed Levofloxacin Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-21 18:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Fosun Pharma) announced that subsidiary Yaopharma has obtained National Medical Products Administration (NMPA) approval for its self-developed Levofloxacin Injection (20 ml: 0.5 g, Chemical Class 3.2).</p>\n<p>The injectable fluoroquinolone is cleared for 11 indications covering mild to severe infections, including hospital- and community-acquired pneumonia, acute bacterial sinusitis, skin and urinary tract infections, chronic bacterial prostatitis, and post-exposure inhalational anthrax.</p>\n<p>Key registration details  \n• Marketing authorisation holder & manufacturer: Yaopharma Co., Ltd.  \n• Drug approval number: Guo Yao Zhun Zi H20264412</p>\n<p>Investment and market context  \n• Cumulative R&D spending: RMB1.94 million (unaudited) through April 2026.  \n• 2025 domestic sales of comparable levofloxacin injections reached RMB1.06 billion, according to IQVIA CHPA.</p>\n<p>Management notes that market launch will broaden Fosun Pharma’s anti-infective pipeline, while actual sales will depend on demand, competitive landscape and channel penetration, and therefore remain uncertain.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1132812937","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132812937","pubTimestamp":1779357783,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Fosun Pharma) announced that subsidiary Yaopharma has obtained National Medical Products Administration (NMPA) approval for its self-developed Levofloxacin Injection...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药开发的左氧氟沙星注射液获NMPA批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Fosun Pharma) announced that subsidiary Yaopharma has obtained National Medical Products Administration (NMPA) approval for its self-developed Levofloxacin Injection (20 ml: 0.5 g, Chemical Class 3.2).\nThe injectable fluoroquinolone is cleared for 11 indications covering mild to severe infections, including hospital- and community-acquired pneumonia, acute bacterial sinusitis, skin and urinary tract infections, chronic bacterial prostatitis, and post-exposure inhalational anthrax.\nKey registration details  \n• Marketing authorisation holder & manufacturer: Yaopharma Co., Ltd.  \n• Drug approval number: Guo Yao Zhun Zi H20264412\nInvestment and market context  \n• Cumulative R&D spending: RMB1.94 million (unaudited) through April 2026.  \n• 2025 domestic sales of comparable levofloxacin injections reached RMB1.06 billion, according to IQVIA CHPA.\nManagement notes that market launch will broaden Fosun Pharma’s anti-infective pipeline, while actual sales will depend on demand, competitive landscape and channel penetration, and therefore remain uncertain.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132812937","isCrawlerRequest":true}